ATE446106T1 - Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier - Google Patents

Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Info

Publication number: ATE446106T1
Authority: AT; Austria
Prior art keywords: animal; human; immune response; pharmaceutical composition; triggering
Prior art date: 2001-11-29

Application number

AT02803755T

Other languages

English (en)

Inventor

Alexei Kirkin

Karine Djandjougazian

Jesper Zeuthen

Original Assignee

Dandrit Biotech As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-29

Filing date

2002-11-29

Publication date

2009-11-15

2002-11-29 Application filed by Dandrit Biotech As filed Critical Dandrit Biotech As

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446106T1 publication Critical patent/ATE446106T1/de

Links

241001465754 Metazoa Species 0.000 title abstract 3
230000028993 immune response Effects 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000000427 antigen Substances 0.000 abstract 5
102000036639 antigens Human genes 0.000 abstract 5
108091007433 antigens Proteins 0.000 abstract 5
206010028980 Neoplasm Diseases 0.000 abstract 3
201000011510 cancer Diseases 0.000 abstract 3
230000004069 differentiation Effects 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
210000001550 testis Anatomy 0.000 abstract 2
210000004443 dendritic cell Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Hematology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT02803755T 2001-11-29 2002-11-29 Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier ATE446106T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200101770		2001-11-29
US33670601P	2001-12-07	2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en)	2001-11-29	2002-11-29	Pharmaceutical composition for inducing an immune response in a human or animal

Publications (1)

Publication Number	Publication Date
ATE446106T1 true ATE446106T1 (de)	2009-11-15

Family

ID=26069102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02803755T ATE446106T1 (de)	2001-11-29	2002-11-29	Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier

Country Status (11)

Country	Link
US (2)	US7771998B2 (de)
EP (1)	EP1448229B1 (de)
JP (1)	JP2005515192A (de)
AT (1)	ATE446106T1 (de)
AU (1)	AU2002365291B2 (de)
DE (1)	DE60234115D1 (de)
DK (1)	DK1448229T3 (de)
ES (1)	ES2335396T3 (de)
IL (1)	IL161832A0 (de)
RU (1)	RU2313365C2 (de)
WO (1)	WO2003045427A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPQ755300A0 (en)	2000-05-17	2000-06-08	Monash University	Immune potentiating compositions
DE10112851C1 (de) *	2001-03-16	2002-10-10	Gsf Forschungszentrum Umwelt	Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
ES2294346T3 (es) *	2002-11-28	2008-04-01	Peter Kufer	Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
CA2587712C (en) *	2004-11-18	2013-02-12	National University Of Corporation Hiroshima University	Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007123591A1 (en)	2006-01-30	2007-11-01	Ludwig Institute For Cancer Research	Ctsp cancer-testis antigens
GB0612342D0 (en) *	2006-06-21	2006-08-02	Glaxosmithkline Biolog Sa	Method
GB0700284D0 (en) *	2007-01-08	2007-02-14	Glaxosmithkline Biolog Sa	Combination therapy
CN101755045B (zh)	2007-05-17	2014-02-12	生物载体株式会社	树突状细胞的制备方法
EP2318040A4 (de) *	2008-07-24	2013-05-01	Univ Central Florida Res Found	Auf krebsstammzellen gerichtete therapie
KR101361416B1 (ko) *	2008-10-08	2014-02-21	인트렉손 코포레이션	다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
KR20120059581A (ko)	2009-08-24	2012-06-08	윌슨 울프 매뉴팩처링	다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
US20130195800A1 (en) *	2010-03-23	2013-08-01	Intrexon Corporation	Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
GB201013443D0 (en) *	2010-08-11	2010-09-22	Cytovac As	Compositions and methods for producing dendritic cells
PH12018501678B1 (en)	2011-08-30	2022-08-10	Astex Pharmaceuticals Inc	Decitabine derivative formulations
CN105288602A (zh) *	2011-10-20	2016-02-03	新干细胞肿瘤学有限责任公司	具有γ干扰素的抗原呈递癌症疫苗
JP5871228B2 (ja) *	2011-10-31	2016-03-01	国立大学法人佐賀大学	慢性副鼻腔炎の検出方法
GB201121308D0 (en)	2011-12-12	2012-01-25	Cell Medica Ltd	Process
EP2812431B1 (de)	2012-02-09	2019-07-17	Baylor College Of Medicine	Peptidmischungen zur erzeugung multiviraler ctl mit breiter spezifität
WO2014007669A1 (ru) *	2012-07-04	2014-01-09	Volgushev Sergei Anatolievich	Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
EP3316685A4 (de)	2015-07-02	2019-03-13	Otsuka Pharmaceutical Co., Ltd.	Lyophilisierte pharmazeutische zusammensetzungen
IL298359B2 (en)	2015-09-18	2025-12-01	Baylor College Medicine	Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520542D0 (en) *	2015-11-23	2016-01-06	Immunocore Ltd & Adaptimmune Ltd	Peptides
EP3661522A2 (de)	2017-08-03	2020-06-10	Otsuka Pharmaceutical Co., Ltd.	Arzneimittelverbindung und reinigungsverfahren dafür
WO2020018413A1 (en)	2018-07-15	2020-01-23	Enochian BioPharma, Inc.	Methods and compositions using recombinant dendritic cells for cancer therapy
EP3903811A1 (de)	2020-05-01	2021-11-03	R.G.C.C. Holdings AG	Pharmazeutische zusammensetzung und verfahren zur induzierung einer immunantwort
EP3981425A1 (de)	2020-10-12	2022-04-13	R.G.C.C. Holdings AG	Sars-cov-2-impfstoffe
CA3119597C (en)	2020-10-12	2023-07-11	R.G.C.C. Holdings AG	Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5443832A (en) *	1990-04-16	1995-08-22	Institut Swisse De Recherches Experimentales Sur Le Cancer	Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
AU2087401A (en)	1999-12-10	2001-06-18	Epimmune, Inc.	Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040241176A1 (en) *	2000-04-27	2004-12-02	Ap Cells. Inc.	Method of producing membrane vesicles
US20040087532A1 (en)	2001-03-09	2004-05-06	Banchereau Jacques F.	Method of treating malignancies through induction of blood immune responses

2002
- 2002-11-29 DK DK02803755.4T patent/DK1448229T3/da active
- 2002-11-29 DE DE60234115T patent/DE60234115D1/de not_active Expired - Lifetime
- 2002-11-29 AT AT02803755T patent/ATE446106T1/de not_active IP Right Cessation
- 2002-11-29 IL IL16183202A patent/IL161832A0/xx unknown
- 2002-11-29 AU AU2002365291A patent/AU2002365291B2/en not_active Expired
- 2002-11-29 EP EP02803755A patent/EP1448229B1/de not_active Expired - Lifetime
- 2002-11-29 ES ES02803755T patent/ES2335396T3/es not_active Expired - Lifetime
- 2002-11-29 WO PCT/DK2002/000802 patent/WO2003045427A2/en not_active Ceased
- 2002-11-29 RU RU2004119548/13A patent/RU2313365C2/ru active
- 2002-11-29 US US10/495,511 patent/US7771998B2/en not_active Expired - Lifetime
- 2002-11-29 JP JP2003546928A patent/JP2005515192A/ja active Pending
2008
- 2008-07-29 US US12/182,089 patent/US7723107B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20090029457A1 (en)	2009-01-29
RU2004119548A (ru)	2005-03-27
US20060051324A1 (en)	2006-03-09
WO2003045427A2 (en)	2003-06-05
IL161832A0 (en)	2005-11-20
DK1448229T3 (da)	2010-03-08
RU2313365C2 (ru)	2007-12-27
DE60234115D1 (de)	2009-12-03
US7723107B2 (en)	2010-05-25
US7771998B2 (en)	2010-08-10
HK1086750A1 (zh)	2006-09-29
ES2335396T3 (es)	2010-03-26
AU2002365291A1 (en)	2003-06-10
EP1448229A2 (de)	2004-08-25
JP2005515192A (ja)	2005-05-26
WO2003045427A3 (en)	2004-03-25
EP1448229B1 (de)	2009-10-21
AU2002365291B2 (en)	2007-11-01

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60234115D1 (de)	2009-12-03	Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
TR199800607T1 (xx)	1998-06-22	Dendritik h�cre uyar�c� fakt�r�.
ES2184769T3 (es)	2003-04-16	Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
ECSP105739A (es)	2010-06-29	Anticuerpos de neutralización contra gdf-8
ATE199096T1 (de)	2001-02-15	Il-11 aus säugetier
DE69734605D1 (de)	2005-12-15	Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ES2093778T3 (es)	1997-01-01	Nuevos anticuerpos y metodos para su uso.
ATA191889A (de)	1994-06-15	Fettsäurezusammensetzung, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung, die sie enthält
AU2002223462A1 (en)	2002-04-22	Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
Liu et al.	2012	Malaria infection alters the expression of B‐cell activating factor resulting in diminished memory antibody responses and survival
ATE114476T1 (de)	1994-12-15	Tierische zelle mit darin eingeführtem antigenem protein.
Araujo Furlan et al.	2018	Limited Foxp3+ regulatory T cells response during acute Trypanosoma cruzi infection is required to allow the emergence of robust parasite-specific CD8+ T cell immunity
NZ322910A (en)	2000-05-26	Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
Liang et al.	2014	Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells
NZ505834A (en)	2002-12-20	Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2004037175A3 (en)	2004-07-29	Compositions and methods for treating human papillomavirus-mediated disease
WO2001068697A3 (en)	2002-05-10	Methods and compositions for immunoregulation
DK0952772T3 (da)	2005-07-18	Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ATE418344T1 (de)	2009-01-15	Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Vahlne et al.	2010	In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL‐2
Moughal et al.	1992	Langerhans cell dynamics in human gingiva during experimentally induced inflammation
Aukrust et al.	1985	Mold allergy-spores and mycelium as allergen sources.
WO2001049821A3 (fr)	2001-12-20	Lignees des lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
DE69929432D1 (de)	2006-04-06	Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
ES2131218T3 (es)	1999-07-16	Utilizacion de anticuerpos anti-idiotipicos para evitar el rechazo hiperagudo de los injertos entre dos especies diferentes.